KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Non-Current Debt (2018 - 2026)

Elanco Animal Health's Non-Current Debt history spans 8 years, with the latest figure at $3.9 billion for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 7.81% to $3.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 billion, a 7.81% decrease, with the full-year FY2025 number at $3.9 billion, down 7.81% from a year prior.
  • Non-Current Debt hit $3.9 billion in Q4 2025 for Elanco Animal Health, roughly flat from $4.0 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for ELAN hit a ceiling of $6.3 billion in Q3 2021 and a floor of $3.9 billion in Q4 2025.
  • Historically, Non-Current Debt has averaged $5.3 billion across 5 years, with a median of $5.5 billion in 2021.
  • Biggest five-year swings in Non-Current Debt: soared 172.95% in 2021 and later dropped 26.52% in 2024.
  • Tracing ELAN's Non-Current Debt over 5 years: stood at $6.0 billion in 2021, then fell by 9.58% to $5.4 billion in 2022, then grew by 5.29% to $5.7 billion in 2023, then fell by 25.44% to $4.3 billion in 2024, then fell by 7.81% to $3.9 billion in 2025.
  • Business Quant data shows Non-Current Debt for ELAN at $3.9 billion in Q4 2025, $4.0 billion in Q3 2025, and $4.1 billion in Q2 2025.